132 related articles for article (PubMed ID: 17343123)
1. [Paroxysmal iatrogenic acne and the epidermal growth factor receptor inhibitors (EGFR)].
Piérard-Franchimont C; Blaise G; Paquet P; Quatresooz R; Rorive A; Piérard GE
Rev Med Liege; 2007 Jan; 62(1):11-4. PubMed ID: 17343123
[TBL] [Abstract][Full Text] [Related]
2. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy.
DeWitt CA; Siroy AE; Stone SP
J Am Acad Dermatol; 2007 Mar; 56(3):500-5. PubMed ID: 17166623
[TBL] [Abstract][Full Text] [Related]
3. EGFR inhibitor-associated acneiform folliculitis: assessment and management.
Duvic M
Am J Clin Dermatol; 2008; 9(5):285-94. PubMed ID: 18717603
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab-induced acne.
Molinari E; De Quatrebarbes J; André T; Aractingi S
Dermatology; 2005; 211(4):330-3. PubMed ID: 16286741
[TBL] [Abstract][Full Text] [Related]
5. [Interdisciplinary management of cutaneous adverse events of EGFR inhibitors and multityrosine kinase inhibitors in oncology].
Livingstone E; Trarbach T; Zimmer L; Schuler M; Schadendorf D
Dtsch Med Wochenschr; 2011 Jan; 136(1-2):39-44. PubMed ID: 21181615
[TBL] [Abstract][Full Text] [Related]
6. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
7. The investigation of the amounts and expressions of epidermal growth factor, epidermal growth factor receptor, and epidermal growth factor receptor gene polymorphisms in acne vulgaris.
Aydingoz IE; Tukenmez Demirci G; Agirbasli D; Oz-Arslan D; Yenmis G
J Cosmet Dermatol; 2021 Jan; 20(1):346-351. PubMed ID: 32421896
[TBL] [Abstract][Full Text] [Related]
8. [Cutaneous side effects of EGF-receptor inhibition and their management].
Gutzmer R; Werfel T; Kapp A; Elsner J
Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
[TBL] [Abstract][Full Text] [Related]
9. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
[TBL] [Abstract][Full Text] [Related]
10. Paronychia induced by the epidermal growth factor receptor inhibitor cetuximab.
Lee SL; Tan BS; Chan LC
J Oncol Pharm Pract; 2013 Sep; 19(3):273-8. PubMed ID: 23161875
[TBL] [Abstract][Full Text] [Related]
11. A status report on drug-associated acne and acneiform eruptions.
Momin SB; Peterson A; Del Rosso JQ
J Drugs Dermatol; 2010 Jun; 9(6):627-36. PubMed ID: 20645524
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous complications of molecular targeted therapy used in oncology.
Lupu I; Voiculescu N; Bacalbasa N; Cojocaru I; Vrancian V; Giurcaneanu C
J Med Life; 2016; 9(1):19-25. PubMed ID: 27974909
[TBL] [Abstract][Full Text] [Related]
13. Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management.
Monjazeb S; Wilson J
Skin Therapy Lett; 2017 Sep; 22(5):5-7. PubMed ID: 28888217
[TBL] [Abstract][Full Text] [Related]
14. [Cutaneous lesions due to inhibition of epidermal growth factor receptor].
Bierhoff E; Seifert HW; Dirschka T
Pathologe; 2006 Feb; 27(1):53-6. PubMed ID: 16362261
[TBL] [Abstract][Full Text] [Related]
15. The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
Wnorowski AM; de Souza A; Chachoua A; Cohen DE
Int J Dermatol; 2012 Feb; 51(2):223-32. PubMed ID: 22250636
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
17. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
18. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
[TBL] [Abstract][Full Text] [Related]
19. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
Lenz HJ
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):5-13. PubMed ID: 16736978
[TBL] [Abstract][Full Text] [Related]
20. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Shin JU; Park JH; Cho BC; Lee JH
Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
